Biosimilars Market to Reach USD 21 Billion in 2022 with a 16.72% CAGR Forecast

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰

The global biosimilars market was valued at US$ 21 Bn. in 2021 and is expected to grow at a CAGR of 16.72 % from 2022 to 2029, reaching US$ 62 Bn. by the end of the forecast period. Factors such as patent expirations of biologics, growing regulatory approvals, and increased adoption of biosimilars in therapeutic areas like oncology and autoimmune diseases are driving this market.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐕𝐢𝐞𝐭𝐧𝐚𝐦

Vietnam's biosimilars market is gaining momentum due to increasing healthcare investments and rising awareness of affordable treatments. Companies like 𝐁𝐢𝐨𝐜𝐨𝐧 are actively exploring partnerships with Vietnamese healthcare providers to expand access to biosimilars. Government support for cost-effective medicines further accelerates growth.

𝐂𝐮𝐫𝐢𝐨𝐮𝐬 𝐭𝐨 𝐩𝐞𝐞𝐤 𝐢𝐧𝐬𝐢𝐝𝐞? 𝐆𝐫𝐚𝐛 𝐲𝐨𝐮𝐫 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐧𝐨𝐰:https://www.maximizemarketresearch.com/request-sample/31668/

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐓𝐡𝐚𝐢𝐥𝐚𝐧𝐝

In Thailand, the demand for biosimilars is driven by the rising prevalence of cancer and autoimmune disorders. 𝐏𝐟𝐢𝐳𝐞𝐫 has introduced biosimilar versions of monoclonal antibodies, targeting these therapeutic areas. The Thai government's focus on healthcare affordability supports the adoption of biosimilars.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧

Japan's biosimilars market is expanding due to its aging population and high healthcare expenditure. Companies like 𝐀𝐦𝐠𝐞𝐧 have partnered with local firms to increase biosimilar penetration. Regulatory initiatives to promote biosimilars, such as streamlined approval processes, provide significant opportunities for growth.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐂𝐨𝐧𝐬𝐨𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐂𝐡𝐢𝐧𝐚

China's biosimilars market is characterized by rapid growth and intense competition. Leading players like 𝐒𝐡𝐚𝐧𝐠𝐡𝐚𝐢 𝐅𝐨𝐬𝐮𝐧 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 are investing in R&D and scaling up production to cater to domestic and global demand. Mergers and acquisitions among Chinese and international firms further consolidate the market.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚

South Korea has emerged as a global leader in biosimilars, with companies like 𝐂𝐞𝐥𝐥𝐭𝐫𝐢𝐨𝐧 and 𝐒𝐚𝐦𝐬𝐮𝐧𝐠 𝐁𝐢𝐨𝐞𝐩𝐢𝐬 spearheading innovation. These companies are focusing on expanding their global footprint through strategic partnerships and regulatory approvals in major markets.

𝐄𝐚𝐠𝐞𝐫 𝐭𝐨 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐰𝐡𝐚𝐭'𝐬 𝐰𝐢𝐭𝐡𝐢𝐧? 𝐒𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐬𝐚𝐦𝐩𝐥𝐞 𝐜𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐭𝐨𝐝𝐚𝐲: https://www.maximizemarketresearch.com/request-sample/31668/

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐒𝐢𝐧𝐠𝐚𝐩𝐨𝐫𝐞

Singapore's biosimilars market benefits from the country's strong focus on biotechnology and innovation. Collaborations between companies like 𝐑𝐨𝐜𝐡𝐞 and local research institutions enhance biosimilar development. Singapore's robust healthcare infrastructure provides a favorable environment for market growth.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐒

The US remains a key market for biosimilars, driven by high healthcare costs and increasing acceptance among healthcare providers. Companies like 𝐒𝐚𝐧𝐝𝐨𝐳 and 𝐓𝐞𝐯𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 are launching biosimilars for blockbuster biologics. Government initiatives to promote biosimilar adoption further support market growth.

𝐁𝐢𝐨𝐬𝐢𝐦𝐢𝐥𝐚𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐔𝐩𝐝𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞

Europe's biosimilars market is the most mature globally, with high adoption rates and strong regulatory support. Companies like Mylan and Biogen are expanding their product portfolios to include biosimilars for oncology and immunology. The region's emphasis on reducing healthcare costs drives sustained growth.

𝐊𝐞𝐲 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬

𝐁𝐢𝐨𝐜𝐨𝐧 expanded its biosimilar portfolio by launching new products in emerging markets.
𝐏𝐟𝐢𝐳𝐞𝐫 received regulatory approval for its biosimilar trastuzumab in multiple countries.
𝐀𝐦𝐠𝐞𝐧 partnered with Japanese firms to enhance biosimilar accessibility in Asia.
𝐂𝐞𝐥𝐥𝐭𝐫𝐢𝐨𝐧 announced plans to build additional manufacturing facilities to meet global demand.
𝐒𝐚𝐧𝐝𝐨𝐳 launched its biosimilar versions of popular biologics in the US and Europe.

𝐆𝐞𝐭 𝐚 𝐜𝐥𝐨𝐬𝐞𝐫 𝐥𝐨𝐨𝐤 𝐚𝐭 𝐭𝐡𝐞 𝐠𝐚𝐦𝐞-𝐜𝐡𝐚𝐧𝐠𝐢𝐧𝐠 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐝𝐫𝐢𝐯𝐢𝐧𝐠 𝐬𝐮𝐜𝐜𝐞𝐬𝐬 :https://www.maximizemarketresearch.com/request-sample/31668/

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

𝐛𝐲 𝐓𝐲𝐩𝐞

Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Granulocyte-colony stimulating factor
Others

Insulin and monoclonal antibodies are anticipated to be the two most rapidly growing segments over the projection period due to One kind of targeted medication therapy is monoclonal antibodies. These medications identify and locate particular proteins on cancerous cells. They either kill the cancer cell or prevent it from proliferating in different ways. Antibodies that have been created and generated from the same parent immune cell are known as monoclonal antibodies. Applications for monoclonal antibodies include research, diagnosis, and therapy of diseases. They are also used to treat osteoporosis, autoimmune diseases, and cancer.

𝐛𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧

Oncology
Inflammatory
Autoimmune diseases
Chronic diseases
Blood disorders
Growth hormone deficiency
Infectious diseases
Other

Due to the higher number of cancer patients and the lower cost of biosimilars compared to innovative biologics, oncology is the largest market segment. The availability of biosimilars has helped oncology by lowering expenses and enhancing the accessibility and affordability of cancer treatment. Furthermore, because cancer is so common, healthcare systems worldwide are focusing on reducing the disease's burden by introducing reasonably priced treatment options.

𝐛𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲

Recombinant DNA Technology
Monoclonal Antibodies (MAb) Technology

𝐛𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

𝐆𝐞𝐭 𝐚 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬:https://www.maximizemarketresearch.com/market-report/global-biosimilars-market/31668/

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

1. Novartis
2. Pfizer
3. Dr. Reddy's Laboratories Ltd
4. Amgen Inc.
5. Eli Lilly and Company
6. Teva Pharmaceutical Industries Ltd
7. Fresenius SE & Co. KGaA
8. STADA Arzneimittel AG
9. Boehringer Ingelheim
10. Gedeon Richter PLC
11. Celltrion
12. Samsung Biologic
13. Coherus BioSciences
14. Biocon Limited
15. Viatris
16. Amega Biotech
17. Apotex
18. Biocad
19. mAbxience
20. Probiomed
21. Fujifilm Kyowa Kirin Biologics
22. Intas Pharmaceuticals Ltd
23. Thermex
24. Reliance Life Sciences
25. Kashiv Biosciences

𝐂𝐡𝐞𝐜𝐤 𝐨𝐮𝐭 𝐨𝐮𝐫 𝐭𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐬𝐭𝐮𝐝𝐢𝐞𝐬 𝐭𝐨 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐬𝐡𝐢𝐟𝐭𝐬 :

♦ India Gaming Market https://www.maximizemarketresearch.com/market-report/india-gaming-market/44686/

♦ Global Imitation Jewelry Market https://www.maximizemarketresearch.com/market-report/global-imitation-jewelry-market/79656/

♦ India Accounting Software Market https://www.maximizemarketresearch.com/market-report/india-accounting-software-market/44134/

♦ India Lithium Ion Battery Market https://www.maximizemarketresearch.com/market-report/india-lithium-ion-battery-market/29994/

♦ India Solar Rooftop Market https://www.maximizemarketresearch.com/market-report/india-solar-rooftop-market/20777/

♦ Global Ayurvedic Market https://www.maximizemarketresearch.com/market-report/global-ayurvedic-market/23882/

♦ Global Vanilla Market https://www.maximizemarketresearch.com/market-report/global-vanilla-market/31727/

♦ Global Banana Powder Market https://www.maximizemarketresearch.com/market-report/global-banana-powder-market/31597/

♦ Saccharin Market https://www.maximizemarketresearch.com/market-report/saccharin-market/188060/

♦ Global Irish Whiskey Market https://www.maximizemarketresearch.com/market-report/global-irish-whiskey-market/94141/

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

MAXIMIZE MARKET RESEARCH PVT. LTD.
3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
+91 9607365656
sales@maximizemarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.

This release was published on openPR.